Media stories about Zynerba Pharmaceuticals (NASDAQ:ZYNE) have trended somewhat positive recently, according to Accern. Accern rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Zynerba Pharmaceuticals earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news coverage about the company an impact score of 47.7746680944187 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) traded up $0.25 during midday trading on Thursday, hitting $11.50. 200,100 shares of the company were exchanged, compared to its average volume of 375,527. The company has a market cap of $155.04 and a P/E ratio of -4.44. Zynerba Pharmaceuticals has a twelve month low of $5.42 and a twelve month high of $25.95.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last announced its quarterly earnings data on Tuesday, November 14th. The company reported ($0.63) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.05). During the same quarter in the previous year, the firm earned ($0.67) EPS. sell-side analysts predict that Zynerba Pharmaceuticals will post -2.49 earnings per share for the current fiscal year.
In related news, major shareholder Michael Rapp acquired 15,000 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were purchased at an average cost of $12.99 per share, with a total value of $194,850.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 9.91% of the company’s stock.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.